Sun Pharmaceutical Industries Limited

150px
Type	Public
Traded as	BSE: 524715 NSE: SUNPHARMA
Industry	Pharmaceuticals
Genre	Generic pharmaceutical company
Founded	1983
Founder(s)	Dilip Shanghvi
Headquarters	Mumbai, India
Key people	Dilip Shanghvi (Chairman and MD) S. Kalyanasundaram (CEO)
Products	Pharmaceuticals, generic drugs
Revenue	5,991 crore (US$1.2 billion) (2011)[1]
Net income	1,907 crore (US$380.45 million) (2011)
Employees	12,000 (2012)
Website	www.sunpharma.com

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is an international pharmaceutical company based in Mumbai, India that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs comprising warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.^[2]

Company[link]

Sun Pharma was established by Mr. Dilip Shanghvi in 1983 in Kolkata with 5 products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology. Some of the top brands of the company include pantocid, susten, aztor, gemer, repace, glucored, strocit, clopilet and cardivas. Over 57% of Sun Pharma sales are from markets outside India, primarily in the US. Manufacturing is across 23 locations, including the US, Canada, Brazil, Mexico and Israel. In the US, the company markets over 200 generics, with another 150 awaiting approval from the USFDA.^[3]

Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company. Today Sun Pharma is the fifth largest and the most profitable pharmaceutical company in India as well as the largest pharmaceutical company by market capitalisation on the Indian exchanges.^[4]

Acquisitions[link]

A large part of Sun Pharma’s growth can be attributed to a number of key acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both USFDA approved today. In 1997, Sun acquired Tamilnadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai, for their strong gynaecology and oncology brands as well as their API and dosage form plant. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.

In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), Chattem Chemicals (2008), and finally Israel based Taro Pharmaceuticals in 2010.^[5]

People[link]

Sun Pharma's Board of Directors include:^[6]

• Dilip S. Shanghvi: Chairman and Managing Director
• Sudhir V. Valia: Executive Director
• Sailesh T. Desai: Executive Director
• S. Kalyanasundaram: Chief Executive Officer
• Hasmukh S. Shah: Non Executive Independent Director
• Keki M. Mistry: Non Executive Independent Director
• Ashwin Dani: Non Executive Independent Director
• S. Mohanchand Dadha: Non Executive Independent Director

SPARC[link]

In 2007, Sun Pharma demerged its R&D arm and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2011, SPARC declared revenue of Rs. 58 crore.^[7] SPARC focuses on new chemical entities (NCE) research and new drug delivery systems (NDDS).^[8]

See Also[link]

• Dilip Shanghvi
• Pharmaceutical industry in India

References[link]

External links[link]

• Official website

v t e BSE SENSEX companies of India As of 19 March 2012: Airtel Bajaj Auto BHEL Cipla Coal India DLF HDFC HDFC Bank Hero MotoCorp Hindalco HUL ICICI Bank Infosys ITC Jaypee Group Jindal Steel & Power KEC International L&T Mahindra & Mahindra Maruti Suzuki NTPC ONGC Reliance Industries SBI Sterlite Industries Sun Pharma Tata Motors Tata Power Tata Steel TCS Wipro

v t e S&P CNX Nifty companies of India As of 19 March 2012: ACC Bajaj Auto BHEL Bharat Petroleum Bharti Airtel Cipla Dabur Dr. Reddy's Laboratories GAIL GlaxoSmithKline Grasim Industries Gujarat Ambuja Cements HCL Technologies HDFC HDFC Bank Hero MotoCorp Hindalco Industries HLL Hindustan Petroleum ICICI Bank Indian Petrochemicals Infosys ITC Limited Jet Airways L&T MTNL Mahindra & Mahindra Mahindra Satyam Maruti Udyog National Aluminium Company NIIT ONGC Oriental Bank of Commerce PNB Ranbaxy Laboratories Reliance Communications Reliance Infrastructure Reliance Industries Siemens SBI SAIL Sun Pharmaceutical Suzlon TCS Tata Motors Tata Power Tata Steel VSNL Wipro Zee